Evidence map›Paper›PMID 34745115›Full record

ArticleFrontiers in immunology2021

Afrakoma Afriyie-Asante, Ankita Dabla, Amy Dagenais, Stefania Berton, Robin Smyth, Jim Sun

Abstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. ESX-5 Deletions inbioRxiv : the preprint server for biology · 2025
    Article
  6. International journal of biological sciences · 2025
    Article
  7. Article
  8. Review
  9. Host Cell Death and Modulation of Immune Response againstInternational journal of molecular sciences · 2024
    Review
  10. Article
  11. Necroptosis in bacterial infections.Frontiers in immunology · 2024
    Review
  12. Virulence Factors ofPathogens (Basel, Switzerland) · 2023
    Review
  13. LncRNA NR_003508 SuppressesInternational journal of molecular sciences · 2023
    Article
  14. Frontiers in cellular and infection microbiology · 2023
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Afrakoma Afriyie-AsanteDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Ankita DablaDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Amy DagenaisDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Stefania BertonDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Robin SmythDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Jim SunDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.

Funding

CIHR PJT-162424
6 · The paper itself

Abstract

Tuberculosis is a deadly, contagious respiratory disease that is caused by the pathogenic bacterium

Indexed as

Cell LineFocal Adhesion Kinase 1Host-Pathogen InteractionsHumansMacrophages, AlveolarMycobacterium tuberculosisNecrosisReactive Oxygen SpeciesTuberculosis, PulmonaryFocal Adhesion Kinase 1PTK2 protein, humanReactive Oxygen Speciesfocal adhesion kinase (FAK)host-directed therapymacrophage cell deathMycobacterium tuberculosis (Mtb)necroptosisprotein tyrosine kinase 2 (PTK2)reactive oxygen species

Identifiers

PMID34745115
PMCPMC8564185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.